Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis
暂无分享,去创建一个
Michael I. Wilson | P. Ratcliffe | K. Eckardt | C. Pugh | P. Maxwell | N. Masson | C. Willam | R. Bicknell | M. Wilson | Y.-M. Tian | S. A. Mahmood | Ya-min Tian | Carsten Willam | Norma Masson
[1] Christopher J. Schofield,et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL , 2002, Nature.
[2] M. Ivan,et al. Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling , 2002, Science.
[3] D. Peet,et al. Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.
[4] P. Ratcliffe,et al. Selection of Mutant CHO Cells with Constitutive Activation of the HIF System and Inactivation of the von Hippel-Lindau Tumor Suppressor* , 2001, The Journal of Biological Chemistry.
[5] G. Semenza,et al. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .
[6] S. McKnight,et al. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.
[7] Michael I. Wilson,et al. C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.
[8] J. M. Arbeit,et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. , 2001, Genes & development.
[9] S. McKnight,et al. Building better vasculature. , 2001, Genes & development.
[10] P. Ratcliffe,et al. Independent function of two destruction domains in hypoxia‐inducible factor‐α chains activated by prolyl hydroxylation , 2001, The EMBO journal.
[11] P. Ratcliffe,et al. Activation of the HIF pathway in cancer. , 2001, Current opinion in genetics & development.
[12] S. White,et al. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. , 2001, Cancer research.
[13] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[14] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[15] G. Waksman,et al. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. , 2001, Cancer research.
[16] P H Watson,et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.
[17] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[18] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[19] Eamonn R. Maher,et al. Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.
[20] M. Goldberg,et al. Angiogenesis Is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1&agr;/VP16 Hybrid Transcription Factor , 2000, Circulation.
[21] P. Carmeliet,et al. PR39, a peptide regulator of angiogenesis , 2000, Nature Medicine.
[22] Napoleone Ferrara,et al. Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.
[23] W. Risau,et al. Angiogenesis in Ischemic Disease , 1999, Thrombosis and Haemostasis.
[24] J. Caro,et al. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. , 1999, Biochemical and biophysical research communications.
[25] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[26] P. Ratcliffe,et al. Oxygen-regulated and Transactivating Domains in Endothelial PAS Protein 1: Comparison with Hypoxia-inducible Factor-1α* , 1999, The Journal of Biological Chemistry.
[27] Natalie A. Lissy,et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.
[28] L. Poellinger,et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of theCBP/p300 coactivator by the hypoxia‐induciblefactor‐1α , 1998, The EMBO journal.
[29] G. Semenza. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.
[30] P. Carmeliet,et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.
[31] R Pasqualini,et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. , 1998, The Journal of clinical investigation.
[32] L. Huang,et al. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .
[33] P. Ratcliffe,et al. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alpha-dependent and -independent hypoxia-inducible gene expression. , 1998, The Journal of biological chemistry.
[34] J. Caro,et al. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. , 1997, The Journal of biological chemistry.
[35] M. Nagao,et al. Activation of Hypoxia-inducible Factor-1; Definition of Regulatory Domains within the α Subunit* , 1997, The Journal of Biological Chemistry.
[36] R. Soldi,et al. The angiogenesis induced by HIV–1 Tat protein is mediated by the Flk–1/KDR receptor on vascular endothelial cells , 1996, Nature Medicine.
[37] M. Gossen,et al. Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.
[38] U. Deuschle,et al. Tetracycline-reversible silencing of eukaryotic promoters , 1995, Molecular and cellular biology.